CCM
RXDX

Cinctive Capital Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Cinctive Capital Management’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-29,640
Closed -$1.12M – 679
2022
Q1 		$1.12M Buy
+29,640
New +$1.17M 0.04% 387

Other funds holding RXDX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cinctive Capital Management's RXDX Position: Q2 2022 in Review

Cinctive Capital Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2022, closing a stake of 29,640 shares — an estimated $1.12M sold.

Cinctive Capital Management first reported a position in RXDX in Q1 2022 and held it in 1 quarter. The position peaked at $1.12M in Q1 2022. 116 funds tracked by Wall St. Rank hold RXDX as of Q2 2022.

  • Cinctive Capital Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Cinctive Capital Management sold 29,640 Prometheus Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $1.12M.
  • Cinctive Capital Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Cinctive Capital Management's Prometheus Biosciences, Inc. Common Stock position peaked at $1.12M in Q1 2022.
  • 116 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2022.

Based on Cinctive Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.